|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nonalcoholic fatty liver disease: Evolving paradigms显示文摘In the last years new evidence has accumulated on nonalcoholic fatty liver disease(NAFLD)challenging the paradigms that had been holding the scene over the previous 30 years.NAFLD has such an epidemic prevalence as to make it impossible to screen general population looking for NAFLD cases.Conversely,focusing on those cohorts of individuals exposed to the highest risk of NAFLD could be a more rational approach.NAFLD,which can be diagnosed with either non-invasive strategies or through liver biopsy,is a pathogenically complex and clinically heterogeneous disease.The existence of metabolic as opposed to genetic-associated disease,notably including'lean NAFLD'has recently been recognized.Moreover,NAFLD is a systemic condition,featuring metabolic,cardiovascular and(hepatic/extrahepatic)cancer risk.Among the clinico-laboratory features of NAFLD we discuss hyperuricemia,insulin resistance,atherosclerosis,gallstones,psoriasis and selected endocrine derangements.NAFLD is a precursor of type 2 diabetes(T2D)and metabolic syndrome and progressive liver disease develops in T2D patients in whom the course of disease is worsened by NAFLD.Finally,lifestyle changes and drug treatment options to be implemented in the individual patient are also critically discussed.In conclusion,this review emphasizes the new concepts on clinical and pathogenic heterogeneity of NAFLD,a systemic disorder with a multifactorial pathogenesis and protean clinical manifestations.It is highly prevalent in certain cohorts of individuals who are thus potentially amenable to selective screening strategies,intensive follow-up schedules for early identification of liver-related and extrahepatic complications and in whom earlier and more aggressive treatment schedules should be carried out whenever possible. | Amedeo Lonardo Fabio Nascimbeni Mauro Maurantonio Alessandra Marrazzo Luca Rinaldi Luigi Elio Adinolfi | 2017 | World Journal of Gastroenterology2017，23，36： | 33 |
| 2 | Risk for cardiovascular events in an Italian population of patients with type 2 diabetes显示文摘 | Pellegrini E Maurantonio M Giannico IM | 2011 | Nutr Metab Cardiovasc Dis2011，21，11： | 1 |
| 3 | Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD显示文摘 | Carulli L Maurantonio M Hebbard L | | 0，，： | 1 |
| 4 | Risk for car- diovascular events in an Italian population of patients with type 2 diabetes 显示文摘 | Pellegrini E Maurantonio M Giannico IM | 2011 | Natr Metab eardiovasc Dis2011，21，11： | 1 |
| 5 | Review article: hyperlipidaemia and cardiovascular risk 显示文摘 | BERTOLOTTI M MAURANTONIO M GABBI C | 2005 | Aliment Pharmacol Ther2005，22，2： | 1 |
| 6 | Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD显示文摘 | Lucia Carulli Mauro Maurantonio Lionel Hebbard Enrica Baldelli Paola Loria Jacob George | 2013 | Current Pharmaceutical Design2013，，29： | 1 |
| 7 | Risk for cardio vascular events in an Italian population of patiems wiih Dpe 2 dm betes显示文摘 | Pellegrini E Maurantonio M Giannico IM e al | 2011 | Nutr Metab Cardiovasc Dis2011，21，11： | 1 |
| 8 | Review article:hyperlipidaemia and cardiovascular risk显示文摘 | BERTOLOTTI M MAURANTONIO M GABBI C | 2005 | Aliment Pharmacol Ther2005，22，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员